Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis.

ABSTRACT:

Objective

To estimate the magnitude of the nocebo response and explore its influencing factors in irritable bowel syndrome (IBS).

Methods

The PubMed, Embase, and Cochrane Library databases were searched up to March 2021. We performed a random effects meta-analysis of the proportion of adverse events (AEs) in placebo-treated patients with IBS who are involved in parallel-designed, randomized, placebo-controlled trials investigating pharmacological interventions and evaluated the effect of trial characteristics on the magnitude of the nocebo response rate.

Results

A total of 6,107 studies were identified from the databases. After evaluation, 53 met the eligibility criteria and were included. The overall pooled nocebo response rate was 32% (95% CI: 26-38%). The most comm

SUBMITTER: Li R 

PROVIDER: S-EPMC9807875 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature